These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

962 related articles for article (PubMed ID: 25591469)

  • 1. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
    Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL
    Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
    Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
    JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.
    Katayama S; Yamada D; Nakayama M; Yamada T; Myoishi M; Kato M; Nowack C; Kolkhof P; Yamasaki Y;
    J Diabetes Complications; 2017 Apr; 31(4):758-765. PubMed ID: 28025025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
    Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Nowack C; Kolkhof P; Ferreira AC; Schloemer P; Filippatos G; ;
    Am J Nephrol; 2019; 50(5):333-344. PubMed ID: 31655812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.
    Snelder N; Heinig R; Drenth HJ; Joseph A; Kolkhof P; Lippert J; Garmann D; Ploeger B; Eissing T
    Clin Pharmacokinet; 2020 Mar; 59(3):359-370. PubMed ID: 31583611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
    Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
    Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
    Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
    Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
    Pitt B; Filippatos G; Agarwal R; Anker SD; Bakris GL; Rossing P; Joseph A; Kolkhof P; Nowack C; Schloemer P; Ruilope LM;
    N Engl J Med; 2021 Dec; 385(24):2252-2263. PubMed ID: 34449181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies.
    Schaefer F; Montini G; Kang HG; Walle JV; Zaritsky J; Schreuder MF; Litwin M; Scalise A; Scott H; Potts J; Iveli P; Breitenstein S; Warady BA
    Trials; 2024 Mar; 25(1):203. PubMed ID: 38509517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
    Filippatos G; Bakris GL; Pitt B; Agarwal R; Rossing P; Ruilope LM; Butler J; Lam CSP; Kolkhof P; Roberts L; Tasto C; Joseph A; Anker SD;
    J Am Coll Cardiol; 2021 Jul; 78(2):142-152. PubMed ID: 34015478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
    Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Rossing P; Kolkhof P; Nowack C; Schloemer P; Joseph A; Filippatos G;
    N Engl J Med; 2020 Dec; 383(23):2219-2229. PubMed ID: 33264825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China.
    Zhou J; Kang L; Gu C; Li X; Guo X; Fang M
    Ren Fail; 2024 Dec; 46(2):2400541. PubMed ID: 39248389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
    Ito S; Shikata K; Nangaku M; Okuda Y; Sawanobori T
    Clin J Am Soc Nephrol; 2019 Aug; 14(8):1161-1172. PubMed ID: 31248950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.
    Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
    Clin J Am Soc Nephrol; 2020 Dec; 15(12):1715-1727. PubMed ID: 33239409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
    Mehdi UF; Adams-Huet B; Raskin P; Vega GL; Toto RD
    J Am Soc Nephrol; 2009 Dec; 20(12):2641-50. PubMed ID: 19926893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.
    Ruilope LM; Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Sarafidis P; Schmieder RE; Joseph A; Rethemeier N; Nowack C; Bakris GL;
    Hypertension; 2022 Dec; 79(12):2685-2695. PubMed ID: 36252131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
    Jacobsen P; Andersen S; Jensen BR; Parving HH
    J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study.
    Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
    Clin Exp Nephrol; 2021 Oct; 25(10):1070-1078. PubMed ID: 34110524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
    Rossing K; Christensen PK; Jensen BR; Parving HH
    Diabetes Care; 2002 Jan; 25(1):95-100. PubMed ID: 11772908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Imarikiren in Patients with Type 2 Diabetes and Microalbuminuria: A Randomized, Controlled Trial.
    Ito S; Kagawa T; Saiki T; Shimizu K; Kuroda S; Sano Y; Umeda Y
    Clin J Am Soc Nephrol; 2019 Mar; 14(3):354-363. PubMed ID: 30755452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.